Haemostatix are seeking a candidate to support drug R&D projects, carrying out laboratory work and running assays. A maximum of one day per week will involve calibrating equipment, washing glass ware and lab administration. A relevant degree is essential.
Haemostatix is developing a new class of coagulant for the control of surgical bleeding. The company's lead product, PeproStat, has recently completed a clinical trial in liver surgery patients. PeproStat is based on a peptide conjugated to recombinant albumin, and is formulated as a sterile solution that is applied topically to an internal wound.
We are now gearing up to progress the product into Phase IIb and beyond. We have a highly innovative platform technology and an exciting pipeline. Our second product, HXP12 ReadyFlow is a purely synthetic peptide formulated in a particulate gel, and is at a pre-clinical stage.
- Salary: up to £25,000
- Based at: BioCity Nottingham